A combined DNA vaccine enhances protective immunity against Mycobacterium tuberculosis and Brucella abortus in the presence of an IL-12 expression vector

Vaccine

Volumn 25, Issue 37-38, 2007, Pages 6744-6754

  Yu, Da Hai ^a   Li, Min ^a   Hu, Xi Dan ^b   Cai, Hong ^a  

^a PEKING UNIVERSITY   (China)

^b Xinjiang Academy of Animal Science   (China)

Author keywords

Brucella abortus; Combined DNA vaccine; IL 12 adjuvant; Mycobacterium tuberculosis; Protective immunity; Th1 immune responses

Indexed keywords

BCG VACCINE; BRUCELLA VACCINE; CD4 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; NITRIC OXIDE; RECOMBINANT INTERLEUKIN 12; TOLL LIKE RECEPTOR;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BRUCELLA ABORTUS; BRUCELLOSIS; CD8+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MONOTHERAPY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TUBERCULOSIS;

ANIMALS; ANTIBODIES; ANTIGENS; BRUCELLA ABORTUS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; GENETIC VECTORS; IMMUNIZATION; INTERLEUKIN-12; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; NITRIC OXIDE; PORE FORMING CYTOTOXIC PROTEINS; RNA, MESSENGER; TOLL-LIKE RECEPTORS; VACCINES, DNA;

EID: 34548292484     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.06.061     Document Type: Article

References (39)

1. Global Tuberculosis Control, Surveillance, Planning, Financing. Report WHO. Geneva: WHO; 2006, p. 1-242.
2. Pappas G., Akritidis N., Bosilkovski M., and Tsianos E. Brucellosis. N Engl J Med 352 22 (2005) 2325-2336
3. Moriyon I., Grillo M.J., Monreal D., Gonzalez D., Marin C., Lopez-Goni I., et al. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet Res 35 1 (2004) 1-38
4. Donnelly J.J., Wahren B., and Liu M.A. DNA vaccines: progress and challenges. J Immunol 175 2 (2005) 633-639
5. Skeiky Y.A., and Sadoff J.C. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4 6 (2006) 469-476
6. Kurar E., and Splitter G.A. Nucleic acid vaccination of Brucella abortus ribosomal L7/L12 gene elicits immune response. Vaccine 15 17-18 (1997) 1851-1857
7. Munoz-Montesino C., Andrews E., Rivers R., Gonzalez-Smith A., Moraga-Cid G., Folch H., et al. Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells. Infect Immun 72 4 (2004) 2081-2087
8. Al-Mariri A., Tibor A., Mertens P., De Bolle X., Michel P., Godefroid J., et al. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect Immun 69 8 (2001) 4816-4822
9. Velikovsky C.A., Cassataro J., Giambartolomei G.H., Goldbaum F.A., Estein S., Bowden R.A., et al. A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. Infect Immun 70 5 (2002) 2507-2511
10. Cassataro J., Estein S.M., Pasquevich K.A., Velikovsky C.A., de la Barrera S., Bowden R., et al. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection. Infect Immun 73 12 (2005) 8079-8088
11. Cassataro J., Velikovsky C.A., de la Barrera S., Estein S.M., Bruno L., Bowden R., et al. A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infect Immun 73 10 (2005) 6537-6546
12. Mayfield J.E., Bricker B.J., Godfrey H., Crosby R.M., Knight D.J., Halling S.M., et al. The cloning, expression and nucleotide sequence of a gene coding for an immunogenic Brucella abortus protein. Gene 63 (1988) 1-9
13. Cai H., Tian X., Hu X.D., Li S.X., Yu D.H., and Zhu Y.X. Combined DNA vaccines formulated either in DDA or in saline protect cattle from Mycobacterium bovis infection. Vaccine 23 (2005) 3887-3895
14. Kamath A.T., Feng C.G., Macdonald M., Briscoe H., and Britton W.J. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 67 4 (1999) 1702-1707
15. Baek K.M., Ko S.Y., Lee M., Lee J.S., Kim J.O., Ko H.J., et al. Comparative analysis of effects of cytokine gene adjuvants on DNA vaccination against Mycobacterium tuberculosis heat shock protein 65. Vaccine 21 25-26 (2003) 3684-3689
16. Triccas J.A., Sun L., Palendira U., and Britton W.J. Comparative affects of plasmid-encoded interleukin 12 and interleukin 18 on the protective efficacy of DNA vaccination against Mycobacterium tuberculosis. Immunol Cell Biol 80 4 (2002) 346-350
17. Pasquali P., Adone R., Gasbarre L.C., Pistoia C., and Ciuchini F. Effect of exogenous interleukin-18 (IL-18) and IL-12 in the course of Brucella abortus 2308 infection in mice. Clin Diagn Lab Immunol 9 2 (2002) 491-492
18. Cai H., Hu X.D., Yu D.H., Li S.X., Tian X., and Zhu Y.X. Combined DNA vaccine encapsulated in microspheres enhanced protection efficacy against Mycobacterium tuberculosis infection of mice. Vaccine 23 32 (2005) 4167-4174
19. Palendira U., Kamath A.T., Feng C.G., Martin E., Chaplin P.J., Triccas J.A., et al. Coexpression of interleukin-12 chains by a self-splicing vector increases the protective cellular immune response of DNA and Mycobacterium bovis BCG vaccines against Mycobacterium tuberculosis. Infect Immun 70 4 (2002) 1949-1956
20. Cai H., Tian X., Hu X.D., Zhuang Y.H., and Zhu Y.X. Combined DNA vaccines formulated in DDA enhance protective immunity against tuberculosis. DNA Cell Biol 23 7 (2004) 450-456
21. Tian X., Cai H., and Zhu YX. Immunogenicity and protection of divalent DNA vaccine encoding antigens MPT83 and MPT64 of Mycobacterium tuberculosis. Zhonghua Yi Xue Za Zhi 85 20 (2005) 1410-1413
22. Shafer-Weaver K., Sayers T., Strobl S., Derby E., Ulderich T., Baseler M., et al. The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med 1 1 (2003) 14
23. Sangari F.J., Garcia-Lobo J.M., and Aguero J. The Brucella abortus vaccine strain B19 carries a deletion in the erythritol catabolic genes. FEMS Microbiol Lett 121 3 (1994) 337-342
24. Zheng L.M., Ojcius D.M., Liu C.C., Kramer M.D., Simon M.M., Parr E.L., et al. Immunogold labeling of perforin and serine esterases in granulated metrial gland cells. FASEB J 5 1 (1991) 79-85
25. Cai H., Yu D.H., Tian X., and Zhu Y.X. Coadministration of interleukin 2 plasmid DNA with combined DNA vaccines significantly enhances the protective efficacy against Mycobacterium tuberculosis. DNA Cell Biol 24 10 (2005) 605-613
26. MacMicking J.D., North R.J., LaCourse R., Mudgett J.S., Shah S.K., and Nathan C.F. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci USA 94 10 (1997) 5243-5248
27. Pan Y., Cai H., Li S.X., Tian X., Li T., and Zhu YX. Combined recombinant DNA vaccine results in significant protection against Mycobacterium tuberculosis. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 35 1 (2003) 71-76
28. Cai H., Yu D.H., Hu X.D., Li S.X., and Zhu Y.X. A combined DNA vaccine-prime, BCG-boost strategy results in better protection against Mycobacterium bovis challenge. DNA Cell Biol 25 8 (2006) 438-447
29. Yu D.H., Li M., Hu X.D., and Cai H. A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses. DNA Cell Biol 26 6 (2007) 435-443
30. Gurunathan S., Klinman D.M., and Seder R.A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18 (2000) 927-974
31. Wozniak T.M., Ryan A.A., Triccas J.A., and Britton W.J. Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection. Infect Immun 74 1 (2006) 557-565
32. Calarota S.A., and Weiner D.B. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev 199 1 (2004) 84-99
33. Cooper A.M., Magram J., Ferrante J., and Orme I.M. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exp Med 186 1 (1997) 39-45
34. Yoshida S., Tanaka T., Kita Y., Kuwayama S., Kanamaru N., Muraki Y., et al. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. Vaccine (2005)
35. Li H., Li R., Zhong S., Ren H., Zou Y., Chen X., et al. The immunogenicity and protective efficacy of Mtb8.4/hIL-12 chimeric gene vaccine. Vaccine 24 9 (2006) 1315-1323
36. Akira S., Uematsu S., and Takeuchi O. Pathogen recognition and innate immunity. Cell 124 4 (2006) 783-801
37. Hornef M.W., Wick M.J., Rhen M., and Normark S. Immune Defence: microbial interference. Nat Immunol 3 (2002) 1033-1040
38. Silverman N., and Maniatis T. NF-κB signaling pathways in mammalian and insect innate immunity. Genes Dev 15 18 (2001) 2321-2342
39. Matsumoto S., Matsumoto M., Umemori K., Ozeki Y., Furugen M., Tatsuo T., et al. DNA augments antigenicity of mycobacterial dna-binding protein 1 and confers protection against Mycobacterium tuberculosis infection in mice. J Immunol 175 1 (2005) 441-449